Literature DB >> 16372167

[Hepatorenal syndrome].

I Kürer1, A Sommerer, G Puhl, U Kaisers, W Boemke.   

Abstract

Hepatorenal syndrome (HRS) is defined as the development of renal insufficiency in chronic liver disease with portal hypertension when other causes of functional renal failure are excluded. Incidence in patients with refractory ascites is 8%, with an overall incidence of renal failure in end stage liver disease being 75%. HRS is predictive for the prognosis of end stage liver failure but its pathogenesis is complex and currently not fully understood.

Entities:  

Mesh:

Year:  2006        PMID: 16372167     DOI: 10.1007/s00101-005-0957-4

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  46 in total

1.  Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group.

Authors:  R Bellomo; M Chapman; S Finfer; K Hickling; J Myburgh
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

2.  Which patients benefit from hemodialysis therapy in hepatorenal syndrome?

Authors:  Oliver Witzke; Markus Baumann; Daniel Patschan; Susann Patschan; Anna Mitchell; Ulrich Treichel; Guido Gerken; Thomas Philipp; Andreas Kribben
Journal:  J Gastroenterol Hepatol       Date:  2004-12       Impact factor: 4.029

3.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

Authors:  Richard Moreau; Francois Durand; Thierry Poynard; Christian Duhamel; Jean-Paul Cervoni; Philippe Ichaï; Armand Abergel; Chantal Halimi; Mathieu Pauwels; Jean-Pierre Bronowicki; Emile Giostra; Cathy Fleurot; Danielle Gurnot; Olivier Nouel; Philippe Renard; Michel Rivoal; Pierre Blanc; Dimitri Coumaros; Sylvie Ducloux; Stephane Levy; Alexandre Pariente; Jean-Marc Perarnau; Jean Roche; Myriam Scribe-Outtas; Dominique Valla; Brigitte Bernard; Didier Samuel; Joël Butel; Antoine Hadengue; Andrzej Platek; Didier Lebrec; Jean-Francois Cadranel
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

4.  Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease.

Authors:  M H Koppel; J W Coburn; M M Mims; H Goldstein; J D Boyle; M E Rubini
Journal:  N Engl J Med       Date:  1969-06-19       Impact factor: 91.245

Review 5.  Liver transplantation as ultimate tool to treat portal hypertension.

Authors:  J Klupp; S Kohler; A Pascher; P Neuhaus
Journal:  Dig Dis       Date:  2005       Impact factor: 2.404

6.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

Authors:  E Akriviadis; R Botla; W Briggs; S Han; T Reynolds; O Shakil
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

7.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.

Authors:  A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

Review 8.  Hepatorenal syndrome.

Authors:  Pere Ginès; Mónica Guevara; Vicente Arroyo; Juan Rodés
Journal:  Lancet       Date:  2003-11-29       Impact factor: 79.321

9.  Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure.

Authors:  A Davenport; E J Will; A M Davison
Journal:  Kidney Int Suppl       Date:  1993-06       Impact factor: 10.545

10.  Modular extracorporeal liver support.

Authors:  Igor M Sauer; Joerg C Gerlach
Journal:  Artif Organs       Date:  2002-08       Impact factor: 3.094

View more
  1 in total

Review 1.  [Chronic critically ill patients from a gastroenterological perspective].

Authors:  M Bittinger; H Messmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-02-21       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.